Form 4: Zenas BioPharma Director John Orloff Granted 18,500 Stock Options

Zenas BioPharma, Inc. Director John J. Orloff was granted 18,500 stock options with an exercise price of $11.94, vesting fully on June 10, 2026.

Summary

• John J. Orloff, a Director of Zenas BioPharma, Inc. (ZBIO), reported the acquisition of derivative securities.
• The transaction involved the grant of 18,500 stock options (Right to Buy) on June 10, 2025.
• Each option has an exercise price of $11.94.
• The options will vest as to 100% of the underlying shares of common stock on June 10, 2026, which is the first anniversary of the vesting commencement date, contingent upon continued service.
• The expiration date for these stock options is June 10, 2035.
• Following this reported transaction, Mr. Orloff beneficially owns 18,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a routine compensation event (stock option grant) to a director. This is generally a neutral to slightly positive event as it aligns director interests with shareholders, but it does not indicate significant operational or financial news.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of compensation for directors, indicating routine corporate governance practices.

Risks

• The value of the stock options is dependent on the future market price of Zenas BioPharma's common stock exceeding the exercise price of $11.94.
• The vesting of the options is subject to Mr. Orloff's continued service, meaning the options could be forfeited if service ceases before the vesting date.

Future Outlook

The vesting schedule of the stock options on June 10, 2026, implies an expectation of continued service from Director John J. Orloff for at least one year from the grant date.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align interests with long-term shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of director compensation across the biotech sector, including companies like Moderna, BioNTech, and Regeneron, which frequently use equity incentives to align leadership with company performance.
• The vesting schedule of one year for 100% of the options is a common, though not universal, practice for director grants, often seen in companies aiming for immediate alignment and retention without overly complex multi-year schedules for non-executive directors.

Corporate Governance

Related Party Transactions

• The grant of stock options to John J. Orloff, a Director, constitutes a transaction with a related party as part of his compensation for service to the company.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholder value creation, as the options' value increases with the company's stock price.
• Employees: While not directly impacting employees, such compensation practices are part of the overall corporate governance and compensation framework.

Next Steps

• John J. Orloff's continued service with Zenas BioPharma, Inc. until June 10, 2026, for the options to fully vest.
• Potential exercise of the options by Mr. Orloff at any time between the vesting date and the expiration date, assuming the stock price is above the exercise price.

Key Dates

Keywords

Zenas BioPharma, ZBIO, Form 4, Stock Options, Insider Transaction, Director Compensation, Beneficial Ownership, Equity Compensation, Biopharma